David M Feldser

13PUBLICATIONS

53CO-AUTHORS

Predictive and prognostic markersMolecular targetsLiquid biopsiesCarbon capture engineering (excl. sequestration)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jun 15, 2026

Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer.

|Oct 10, 2025

Primary tumor chromatin landscape governs metastatic organotropism.

Amy C Gladstein, David M Feldser

|Jun 12, 2025

The H3 <sup>K36M</sup> oncohistone inhibits NSD2 to activate a SETD2-dependent antiviral-like immune response in KRAS-driven lung cancer.

Amy C Gladstein, Carson D Poltorack, Akino Mercy Charles Solomon

|Sep 20, 2023

Metastatic Competency and Tumor Spheroid Formation Are Independent Cell States Governed by RB in Lung Adenocarcinoma.

Nelson F Freeburg, Nia Peterson, Dain A Ruiz

|Jul 21, 2023

p53 restoration in small cell lung cancer identifies a latent cyclophilin-dependent necrosis mechanism.

Jonuelle Acosta, Qinglan Li, Nelson F Freeburg

|Mar 10, 2023

Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling.

David M Walter, Amy C Gladstein, Katherine R Doerig

Pageof 3

Frequent Collaborators

Amy C Gladstein

Monte M Winslow

Keren M Adler

Nelson F Freeburg

Min K Tsai

Sarah E Pierce

David M Walter

Vladimir A Tyurin

Yulia Nefedova

Andrew Kossenkov

Frequent Collaborators

Amy C Gladstein

Monte M Winslow

Keren M Adler

Nelson F Freeburg